Discussing Brain Metastases in Breast Cancer

Managing brain metastases has become a difficult problem in patients with breast cancer. 
BY DANIELLE BUCCO
PUBLISHED: FEBRUARY 28, 2017
When it comes to treating breast cancer, brain metastases have become a challenging issue for patients with certain subtypes.

“As many of our systemic therapies have improved, the brain remains a sanctuary site and we're still at the cusp of understanding why certain breast cancer cells find their way to the brain,” said Carey Anders, M.D., associate professor, Department of Medicine, Division of Hematology and Oncology, UNC-Chapel Hill.

In an interview with CURE, Anders discussed available and emerging treatment options for patients with breast cancer that has metastasized to the brain.

Please provide some background on the issue of brain metastases in patients with breast cancer.

Breast cancer brain metastases are becoming more common…We know some of this is subtype dependent, meaning certain subtypes of breast cancer, such as HER2-positive, triple-negative, or basal-like breast cancer, are more likely to metastasize to the brain. We're still trying to understand what those biologic properties are that allow for brain honing. As we're improving systemic therapies, the brain remains the sanctuary site such that cells that have the ability to survive in circulation find their home in the brain. 

Can you discuss some of the systemic therapies?

In my opinion, the most work has been done in the HER2-positive population, so there are a lot of exciting therapies, some old and some new. Lapatinib is probably the most tried and true and has been most extensively studied in HER2-positive brain metastases, but we're seeing the next generation of lapatinib, such as ONT-380, and MM-302, which is a HER2-targeted liposomal doxorubicin. We're also seeing derivatives of irinotecan either it's pro-drug or it's metabolite also packaged into liposomes including the MM-398 compound and then Nectar NKTR-102 compound.

How is the toxicity profile with the HER2+ agents, and how do you decide which treatment to use?

Some of the toxicities associated with HER2+ small molecule inhibitors relate more to how much activity the drug has against EGFR, which is also HER1. When we see HER1 or EGFR inhibition, the toxicities can manifest in skin toxicity with rash, as well as diarrhea. As we've seen these drugs evolve we've moved away from HER1 or EGFR and more toward HER2, not only to have a more potent signaling pathway in the cell but also to minimize the toxicities. 

Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
The Logistics of Multigene Panel Testing in Breast Cancer
Generally, health insurance covers the cost of genetic testing recommended by a physician. However, some patients who had BRCA testing in the past have had trouble getting reimbursed for a follow-up panel test. The outof- pocket cost for a single panel test can be up to $5,000, although lower-cost tests are available.
Exploring Genetic Differences in Men's Breast Cancer
The genetic differences that distinguish men’s breast cancers may lead to new diagnosis and treatment options.
Cancer Stress and Coping With Change
Cancer survivor notices difficulty with changes and transitions since cancer.
Related Videos
Angela Fishbaugh on Discovering Your Story and Skills
Angela Fishbaugh, author of "Angela's Decision," discusses how to discover your skills and story within. 
Sam Smith Explains Cognitive Behavioral Therapy for Patients With Breast Cancer
Sam Smith, University of Leeds, explains cognitive behavioral therapy for patients with breast cancer.
Treatment-Related Side Effects in Breast Cancer Survivors
Halle Moore, M.D., medical oncologist at the Cleveland Clinic, discusses the negative symptoms many breast cancer survivors face, and the treatments that these symptoms were associated with.  
x
//For side ad protocol